Suppr超能文献

[利妥昔单抗成功治疗落叶型天疱疮。3例报告]

[Successful treatment of pemphigus foliaceus with rituximab. Report of 3 cases].

作者信息

Alter M, Wittmann M, Völker B, Kapp A, Werfel T, Gutzmer R

机构信息

Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Medizinische Hochschule Hannover, Ricklinger Strasse 5, 30449, Hannover.

出版信息

Hautarzt. 2009 Sep;60(9):743-8. doi: 10.1007/s00105-008-1682-0.

Abstract

Treatment of autoimmune bullous diseases, especially of the pemphigus diseases, regularly requires the use of immunosuppressive drugs, often with insufficient clinical benefit but considerable side effects. A variety of autoimmune diseases (such as rheumatoid arthritis, lupus erythematosus, pemphigus vulgaris) have been successfully treated with rituximab, a chimeric monoclonal antibody against CD20, leading to a transient depletion of B cells. We report on three patients with pemphigus foliaceus who responded to rituximab after failing multiple other immunosuppressive therapies. We also examine the controversial issue of continuation therapy with rituximab in detail.

摘要

自身免疫性大疱性疾病,尤其是天疱疮疾病的治疗通常需要使用免疫抑制药物,但其临床疗效往往不佳,且副作用较大。利妥昔单抗是一种抗CD20嵌合单克隆抗体,已成功用于治疗多种自身免疫性疾病(如类风湿性关节炎、红斑狼疮、寻常型天疱疮),可导致B细胞短暂耗竭。我们报告了3例落叶型天疱疮患者,他们在多种其他免疫抑制治疗失败后对利妥昔单抗有反应。我们还详细探讨了利妥昔单抗持续治疗这一有争议的问题。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验